Lipid-lowering LPL variants were associated with decreased risks of bladder cancers (OR 0.56; 95% CI: 0.39 to 0.79; p-IVW=1.06×10-3, FDR=5.94×10-3). This evidence concerns the gene LPL and urinary bladder carcinoma.